Macroaxis Stories

Does ARTELO BIOSCIENCES (NASDAQ:ARTL) have steady essential indicators based on the new hike?

January 12, 2021  By Rifka Kats
Macroaxis Story
ARTELO BIOSCIENCES Current Ratio is relatively stable at the moment as compared to the past year. The company's current value of Current Ratio is estimated at 4.96. Debt to Equity Ratio is expected to hike to 0.16 this year, although the value of Earnings before Tax will most likely fall to (4.3 M). One of the important factors of profitable assets selection is to know the future growth potential of an asset before buying its shares. This post will summarize ARTELO BIOSCIENCES. We will analyze why it could be a much better year for ARTELO BIOSCIENCES shareholders. ARTELO BIOSCIENCES INC probability of distress is under 43 percent. Will ARTELO BIOSCIENCES stakeholders continue to pick up in February?
Published over a year ago
View all stories for Artelo Biosciences | View All Stories

Reviewed by Vlad Skutelnik

ARTELO BIOSCIENCES appears to be abnormally volatile, given 1 month investment horizon. ARTELO BIOSCIENCES INC secures Sharpe Ratio (or Efficiency) of 0.0906, which signifies that the company had 0.0906% of return per unit of risk over the last month. Our philosophy in foreseeing the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. By analyzing ARTELO BIOSCIENCES INC technical indicators you can now evaluate if the expected return of 0.54% is justified by implied risk. Please makes use of ARTELO BIOSCIENCES INC risk adjusted performance of 0.0568, and Mean Deviation of 4.63 to double-check if our risk estimates are consistent with your expectations.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Artelo Biosciences income statement, its balance sheet, and the statement of cash flows. Potential Artelo Biosciences investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Artelo Biosciences investors may use each financial statement separately, they are all related. The changes in Artelo Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Artelo Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Artelo Biosciences fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Artelo Biosciences performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Artelo Biosciences shares is the value that is considered the true value of the share. If the intrinsic value of Artelo is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Artelo Biosciences. Please read more on our fundamental analysis page.

Watch out for price decline

Please consider monitoring Artelo Biosciences on a daily basis if you are holding a position in it. Artelo Biosciences is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Artelo Biosciences stock to be traded above the $1 level to remain listed. If Artelo Biosciences stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How effective is Artelo Biosciences in utilizing its assets?

Artelo Biosciences reports assets on its Balance Sheet. It represents the amount of Artelo resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Artelo Biosciences aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Pharmaceuticals space. To get a better handle on how balance sheet or income statements item affect Artelo volatility, please check the breakdown of all its fundamentals.

Are Artelo Biosciences Earnings Expected to grow?

The future earnings power of Artelo Biosciences involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Artelo Biosciences factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Artelo Biosciences stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Artelo expected earnings.

Artelo Biosciences Gross Profit

Artelo Biosciences Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Artelo Biosciences previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Artelo Biosciences Gross Profit growth over the last 10 years. Please check Artelo Biosciences' gross profit and other fundamental indicators for more details.

Detailed Perspective On Artelo Biosciences

The company reported the previous year's revenue of 212.82 M. Net Loss for the year was (4.65 M) with profit before overhead, payroll, taxes, and interest of 83.01 M.

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ARTELO BIOSCIENCES has an asset utilization ratio of 138.85 percent. This denotes that the company is making $1.39 for each dollar of assets. An increasing asset utilization means that ARTELO BIOSCIENCES INC is more efficient with each dollar of assets it utilizes for everyday operations.
Current Assets
2.9 M		Assets Non Current
2 M		Goodwill
1.8 M
Current Assets2.9 Million42.98
Assets Non Current2.02 Million29.97
Goodwill1.82 Million27.05

Is ARTELO BIOSCIENCES pull down permanent?

New Information Ratio is up to 0.02. Price may pull down again. ARTELO BIOSCIENCES INC exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate ARTELO BIOSCIENCES INC individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about ARTELO BIOSCIENCES future systematic risk. ARTELO BIOSCIENCES INC is a potential penny stock. Although ARTELO BIOSCIENCES may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in ARTELO BIOSCIENCES INC. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

While other companies in the biotechnology industry are either recovering or due for a correction, ARTELO BIOSCIENCES may not be performing as strong as the other in terms of long-term growth potentials. With a less-than optimistic outlook for your 30 days horizon, it may be a good time to drop some or all of your ARTELO BIOSCIENCES holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to ARTELO BIOSCIENCES.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Artelo Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com